VCYT: Cup Handle detected on 4 Jun 2026

VCYT has formed a cup-and-handle pattern after a sharp rally from Q1 earnings (May 5) that drove the stock to $41.19, with the pattern now consolidating near current price of $48.69. The overall pattern quality scores 80/98—strong structure (15/15), moderate volume confirmation (12/12), and solid breakout signal (13/13). The setup sits 3.98% below its 52-week high, suggesting breakout potential above $41.19 resistance. RSI at 72.29 signals overbought conditions, which can precede pullback or consolidation before continuation. Volume ratio of 1.13× average indicates modest demand support; the pattern requires sustained volume on any breakout to confirm.

Veracyte reported Q1 2026 revenue of $139.1 million and testing revenue of $135.1 million, representing year-over-year increases of 21% and 26%, respectively. Management noted that Decipher and Afirma volume growth surpassed expectations. The stock jumped 25% on May 6, closing at $41.19, and has climbed another 18% since then to $48.69. The company raised full-year 2026 revenue and margin guidance—to $582M–$592M revenue. Jefferies initiated coverage with a Buy rating and $45 target, while Canaccord adjusted its target to $40 on Hold. Upcoming product launches of Prosigna LDT and TrueMRD are expected to drive market expansion. This pattern forms in a window of positive momentum and raised guidance, but the stock has already moved significantly from earnings.

A successful cup-and-handle breakout would target $53.03 (conservative measure move)—a 8.9% move from current $48.69. The pattern suggests continued upside if volume confirms the breakout; historical win probability stands at 54.49%, indicating modest edge. Volume needs to exceed the 1.13× ratio on breakout days to validate the setup. Invalidation occurs at $37.66 (key support), a breakdown that would signal pattern failure and reverse the bullish thesis. The handle structure and recent bullish engulfing (detected June 2) add confluence, though RSI overbought conditions suggest entry timing risk near current levels.

RSI at 72.29 indicates overbought conditions—aggressive entry here risks immediate pullback before continuation. The stock has already gained 45.56% in one month and 9.44% in the last week, suggesting significant advance-decline risk; mean reversion could test $41.19 resistance or drop toward $37.66 support. Growing pricing and reimbursement pressure on key tests represents a potential headwind. Beta of 1.27 signals elevated volatility relative to market, increasing whipsaw risk. Analyst sentiment remains mixed: Jefferies Buy vs. Canaccord Hold suggests no unanimous conviction. No near-term earnings catalysts visible; the next major event is clinical data presentation at AUA 2026, which carries both upside and downside risk if results disappoint.